Latanoprost/Timolol Elvim

Timolol maleate and Latanoprost, the active ingredients in Latanoprost/Timolol Elvim, are a beta‑blocker and a prostaglandin analog presented as an ophthalmic solution for ocular use. They lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanoprost/Timolol Elvim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol Elvim is used in the management of glaucoma‑related conditions to reduce intra‑ocular pressure.

- Open‑angle glaucoma: lowers eye pressure to prevent optic nerve damage. - Ocular hypertension: reduces elevated eye pressure and lowers risk of progression to glaucoma. - Secondary open‑angle glaucoma: provides pressure‑lowering effect similar to primary disease.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Conjunctival hyperemia (red eye). - Itching or mild allergic‑type reaction on the eyelid. - Dry eye or foreign‑body sensation. - Increased eyelash growth.

Serious or Rare Side Effects: - Severe ocular pain or sudden vision loss. - Allergic angioedema affecting the eye or periorbital tissues. - Systemic bradycardia, hypotension, or exacerbation of asthma. - Corneal ulceration or keratitis. - Persistent intra‑ocular pressure rise despite therapy.

Before prescribing Latanoprost/Timolol Elvim, clinicians should consider several safety factors.

- Cardiovascular assessment: monitor heart rate and blood pressure due to beta‑blocker effects. - Respiratory status: avoid in patients with asthma or severe COPD. - Intra‑ocular pressure monitoring: ensure adequate pressure reduction and watch for hypotony. - Sulfonamide allergy: check for hypersensitivity to preservative components. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost/Timolol Elvim may interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid):\n- Systemic non‑selective beta‑blockers (e.g., propranolol): additive bradycardia and hypotension. - Topical ocular beta‑blockers: increased systemic beta‑blockade risk. - Systemic adrenergic agonists (e.g., epinephrine): may diminish intra‑ocular pressure‑lowering effect. - Carbonic anhydrase inhibitors (oral or topical): excessive IOP reduction leading to hypotony.

Moderate Interactions (Monitor Closely): - Inhaled beta‑agonists (e.g., albuterol): may reduce ocular beta‑blocker efficacy. - Anticholinergic eye drops: potential ocular surface irritation. - Topical NSAIDs: heightened risk of corneal complications. - Calcium channel blockers: possible additive cardiovascular effects.